Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort
| Title: | Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort |
|---|---|
| Authors: | Wong K; Pitcher D; Braddon F; Downward L; Steenkamp R; Annear N; Barratt J; Bingham C; Chrysochou C; Coward RJ; Game D; Griffin S; Hall M; Johnson S; Kanigicherla D; Karet Frankl F; Kavanagh D; Kerecuk L; Maher ER; Moochhala S; Pinney J; Sayer JA; Simms R; Sinha S; Srivastava S; Tam FWK; Turner AN; Walsh SB; Waters A; Wilson P; Wong E; Taylor CM; Nitsch D; Saleem M; Bockenhauer D; Bramham K; Gale DP; Abat S; Adalat S; Agbonmwandolor J; Ahmad Z; Alejmi A; Almasarwah R; Asgari E; Ayers A; Baharani J; Balasubramaniam G; Kpodo F; Bansal T; Barratt A; Bates M; Bayne N; Bendle J; Benyon S; Bergmann C; Bhandari S; Boddana P; Bond S; Branson A; Brearey S; Brocklebank V; Budwal S; Byrne C; Cairns H; Camilleri B; Campbell G; Capell A; Carmody M; Carson M; Cathcart T; Catley C; Cesar K; Chan M; Chea H; Chess J; Cheung CK; Chick K-J; Chitalia N; Christian M; Chrysochou T; Clark K; Clayton C; Clissold R; Cockerill H; Coelho J; Colby E; Colclough V; Conway E; Cook HT; Cook W; Cooper T; Crosbie S; Cserep G; Date A; Davidson K; Davies A; Dhaun N; Dhaygude A; Diskin L; Dixit A; Doctolero E; Dorey S; Downard L; Drayson M; Dreyer G; Dutt T; Etuk K; Evans D; Finch J; Flinter F; Fotheringham J; Francis L; Gallagher H; Garcia E; Gavrila M; Gear S; Geddes C; Gilchrist M; Gittus M; Goggolidou P; Goldsmith C; Gooden P; Goodlife A; Goodwin P; Grammatikopoulos T; Gray B; Griffith M; Gumus S; Gupta S; Hamilton P; Harper L; Harris T; Haskell L; Hayward S; Hegde S; Hendry B; Hewins S; Hewitson N; Hillman K; Hiremath M; Howson A; Htet Z; Huish S; Hull R; Humphries A; Hunt DPJ; Hunter K; Hunter S; Ijeomah-Orji M; Inston N; Jayne D; Jenfa G; Jenkins A; Jones CA; Jones C; Jones A; Jones R; Kamesh L; Karim M; Kaur A; Kearley K; Khwaja A; King G; Kislowska E; Klata E; Kokocinska M; Lambie M; Lawless L; Ledson T; Lennon R; Levine AP; Lai LWM; Lipkin G; Lovitt G; Lyons P; Mabillard H; Mackintosh K; Mahdi K; Maher E; Marchbank KJ; Mark PB; Masoud S; Masunda B; Mavani Z; Mayfair J; McAdoo S; Mckinnell J; Melhem N; Meyrick S; Morgan P; Morgan A; Muhammad F; Murray S; Novobritskaya K; Ong AC; Oni L; Osmaston K; Padmanabhan N; Parkes S; Patrick J; Pattison J; Paul R; Percival R; Perkins SJ; Persu A; Petchey WG; Pickering MC; Plumb L; Plummer Z; Popoola J; Post F; Power A; Pratt G; Pusey C; Rabara R; Rabuya M; Raju T; Javier C; Roberts ISD; Roufosse C; Rumjon A; Salama A; Sandford R; Sandu KS; Sarween N; Sebire N; Selvaskandan H; Sharma A; Sharples EJ; Sheerin N; Shetty H; Shroff R; Sinha M; Smith K; Smith L; Stott I; Stroud K; Swift P; Szklarzewicz J; Tam F; Tan K; Taylor R; Tischkowitz M; Thomas K; Tse Y; Turnbull A; Tyerman K; Usher M; Venkat-Raman G; Walker A; Watt A; Webster P; Wechalekar A; Welsh GI; West N; Wheeler D; Wiles K; Willcocks L; Williams A; Williams E; Williams K; Wilson DH; Wilson PD; Winyard P; Wood G; Woodward E; Woodward L; Woolf A; Wright D |
| Source: | The Lancet, 2024 |
| Publisher Information: | Elsevier B.V. |
| Publication Year: | 2024 |
| Collection: | Newcastle University Library ePrints Service |
| Description: | © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: Individuals with rare kidney diseases account for 5–10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure. Methods: People aged 0–96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan–Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window). Findings: Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9–16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p |
| Document Type: | article in journal/newspaper |
| File Description: | application/pdf |
| Language: | unknown |
| Relation: | https://eprints.ncl.ac.uk/297646; https://eprints.ncl.ac.uk/fulltext.aspx?url=297646/2E480D37-0357-4AE4-8210-D326CC0E0813.pdf&pub_id=297646 |
| Availability: | https://eprints.ncl.ac.uk/297646 |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: | edsbas.403FA82E |
| Database: | BASE |